[1] | Kannangai R, Kandathil AJ, Ebenezer DL, et al: Usefulness of Alternate Prognostic Serum and Plasma Markers for Antiretroviral Therapy for Human Immunodeficiency Virus Type 1 Infection . Clinical. and Vaccine Immunology. 2008, 15:154-158. |
|
[2] | Kapiga SH, Mwakagile D, Spiegelman D, Msamanga GI, Hunter D, Fawzi WW: Predictors of CD4+ lymphocyte count among HIV-seropositive and HIV-seronegative pregnant women in Dar es Salaam, Tanzania. East Afr Med J. 2000, 77:206-211. |
|
[3] | Sen S, Vyas A, Sanghi S, Shanmuganandan K, et al: Correlation of CD4+ T cell Count with Total Lymphocyte Count, Haemoglobin and Erythrocyte Sedimentation Rate Levels in Human Immunodeficiency Virus Type-l Disease. MJAFI. 2011, 67:15-20. |
|
[4] | Shah S, Smith CJ, Lampe F, Youle M, Johnson MA, Phillips AN, Sabin CA: Haemoglobin and albumin as markers of HIV disease progression in the highly activeantiretrovial therapy era: relationships with gender. HIV Med. 2007, 8:38-45. |
|
[5] | Dao CN, Peters PJ, Kiarie JN, et al: Hyponatremia, hypochloremia, and hypoalbuminemia predict an increased risk of mortality during the first year of antiretroviral therapy among HIV-infected Zambian and Kenyan women. AIDS Res Hum Retroviruses. 2011, 27:1149-55. |
|
[6] | Kamya MR, Semitala FC, Quinn TC, et al: Total lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda. African Health Sciences. 2004, 4:94-101. |
|
[7] | Balakrishnan P, Solomon S, Kumarasamy N, Mayer KH: Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. Indian J Med Res. 2005, 121:345-355. |
|
[8] | Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J: Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis. 2005, 40:853-8. |
|
[9] | Collini P, Schwab U, Sarfo S, Obeng-Baah J, Norman B, Chadwick D, Bibby D, Bedu-Addo G: Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort. Clin Infect Dis. 2009, 48:988-91. |
|
[10] | Langford SE, Ananworanich J, Cooper DA: Predictors of disease progression in HIV infection: A review. AIDS Res Ther. 2007, 4:11. |
|
[11] | Ramana KV: HIV: Disease Management in the Highly Active Antiretroviral Therapy (HAART) Era. J Medical Microbiol Diagnosis. 2012, 1:101. |
|
[12] | Venkataramana K: A Study of Biological Markers in HIV Disease Progression and Management in the Highly Active Antiretroviral Therapy (HAART) Era. American Journal of Bioscience and bioengineering. 2013, 1:24-37. |
|
[13] | Ramana KV: Are we Close Enough to get rid of. International Journal of Molecular Medical Science. 2013, 3:25-29. |
|
[14] | Ramana KV, Sabitha V, Rao R: A: Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ Cell Counts and Disease Progression in Resource Poor Settings in Highly Active Antiretroviral Therapy (HAART) Era. J Clin Diagn Res. 2013, 7:1332-5. |
|
[15] | Ramana KV, Rao R: Human immunodeficiency virus disease management in highly active antiretroviral therapy era: A comprehensive review. Ann Trop Med Public Health. 2013, 6:5-9. |
|
[16] | Ramana KV, Rao R, Kandi S, Singh PA, Kumar VP: Elevated activities of serum lactate dehydrogenase in human immunodeficiency virus sero-positive patients in highly active antiretroviral therapy era. J Dr NTR Univ Health Sci. 2013, 2: 162-6. |
|
[17] | Ramana KV: Markers of HIV-1 Disease Progression. American Journal of Infectious Diseases and Microbiology. 2013, 1:96-100. |
|
[18] | Ramana KV: Effect of Highly Active Antiretroviral Therapy (HAART) on Human Immunodeficiency Virus Disease Pathogenesis. and Progression. American Journal of Public Health. 2014, 2:68-74. |
|
[19] | Kandi V: Effect of co-morbidities on disease course in human immunodeficiency virus-infected illicit drug users in the era of highly active antiretroviral therapy. Epidemiol Health. 2015, 37:2015008. |
|